

16 LD

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

FIKES *et al.*

Appl. No. 09/583,200

Filed: May 30, 2000

For: **HLA Class I A2 Tumor  
Associated Antigen Peptides and  
Vaccine Compositions**

Confirmation No. 1443

Art Unit: 1644

Examiner: Schwadron, R.B.

Atty. Docket: 2060.0150002/HCC/PAC

**Amendment and Submission of Substitute Sequence Listing  
Under 37 C.F.R. § 1.825(a)**

RECEIVED  
TECH CENTER 1600/2900  
03 FEB 19 PM 3:28

Commissioner for Patents  
Washington, D.C. 20231

Sir:

In reply to the Notice to Comply with Requirements for Patent Applications Containing Nucleotide Sequence and/or amino acid Sequence Disclosures dated **January 15, 2003**, in the above identified matter, and in advance of prosecution, Applicants submit the following Amendment and Remarks. This Amendment is provided in the following format:

- (A) A clean version of each replacement paragraph/page along with clear instructions for entry;
- (B) Starting on a separate page, appropriate remarks and arguments. 37 C.F.R. § 1.121 and MPEP 714; and
- (C) Starting on a separate page, a marked-up version entitled: "Version with markings to show changes made."

**RECEIVED**

MAR 03 2003

TECH CENTER 1600/2900